• 1
    Melton L, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective: how many women have osteoporosis? J Bone Miner Res 1992; 7: 10510.
  • 2
    Silverman SL, Madison RE. Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California Hospital Discharge Data. Am J Public Health 1988; 78: 14823.
  • 3
    Wehren LE, Hawkes WG, Orwig DL, Hebrel JR, Zimmerman SI, Magaziner J. Gender differences in mortality after hip fracture: the role of infection. J Bone Miner Res 2003; 18: 22317.
  • 4
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Conner E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1988; 280: 207782.
  • 5
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on risk of hip fracture in elderly women. N Engl J Med 2001; 344: 33340.
  • 6
    Delmas PD, Recker RR, Chestnut CH III, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporsis Int 2004; 15: 7928.
  • 7
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 180922.
  • 8
    Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 101322.
  • 9
    Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Int Med 2005; 165: 24149.
  • 10
    Roerholt C, Eiken P, Abrahamsen B. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporosis Int 2009; 20: 299307.
  • 11
    Tosteson AN, Do TP, Wade SW, Anthony MS, Downs RW. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int 2010; 21: 176980.
  • 12
    Hansen KE, Senson ED, Baltz B, Shuna AA, Jones AN, Elliott ME. Adherence to alendronate in male veterans. Osteoporosis Int 2008; 19: 34956.
  • 13
    Grazio S, Babic-Naglic D, Kehler T, Curkovic B. Persistence of weekly alendronate: a real-world study in Croatia. Clin Rheumatol 2008; 27: 6513.
  • 14
    Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152: 94351.
  • 15
    Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25: 12829.
  • 16
    Sambrook P, Nguyen T. Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy [letter]. Br J Rheumatol 1992; 31: 5734.
  • 17
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 18
    Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, et al. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 2011; 50: 1019.
  • 19
    Mikuls TR, Kazi S, Cipher D, Hooker R, Kerr GS, Richards JS, et al. The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol 2007; 34: 14804.
  • 20
    Department of Veterans Affairs. Pharmacy Benefits Management services. URL:
  • 21
    Sales MM, Cunningham FE, Glassman PA, Valentino MA, Good CB. Pharmacy benefits management in the Veterans Administration: 1995 to 2003. Am J Manage Care 2005; 11: 10412.
  • 22
    Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 56574.
  • 23
    Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al. Merging Veterans Affairs Rheumatoid Arthritis registry and pharmacy data to access methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) 2011; 63: 168090.
  • 24
    Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 10038.
  • 25
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 6139.
  • 26
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 27
    Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol 2005; 32: 14329.
  • 28
    Pincus T, Swearingen C, Wolfe F. Toward a Multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly Health Assessment Questionnaire format. Arthritis Rheum 1999; 42: 222030.
  • 29
    Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008; 23: 143541.
  • 30
    Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, et al. Adherence to bisphosphonate therapy and hip fracture risk in women. Osteoporosis Int 2008; 19: 8118.
  • 31
    Roughead EE, Ramsay E, Priess K, Barratt J, Ryan P, Gilbert AL. Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates. Pharmacoepidemiol Drug Saf 2009; 18: 6975.